Vertex Pharmaceuticals stock falls after pain drug fails in Phase 2 study
Barry Sloane, Chairman and CEO of NewtekOne, Inc. (NASDAQ:NEWT), recently acquired a total of 10,000 shares of the company’s common stock. The transactions, dated May 29, 2025, were executed at prices ranging from $10.85 to $10.91 per share, amounting to a total purchase value of $108,610. The purchase was made near the stock’s 52-week low of $9.12, with shares trading at an attractive P/E ratio of 5.6x and offering a substantial 7% dividend yield. Following these transactions, Sloane’s direct ownership in NewtekOne stands at 1,200,459 shares. According to InvestingPro analysis, the company appears undervalued based on its Fair Value estimate, while maintaining its dividend payments for 11 consecutive years. For deeper insights into NewtekOne’s valuation and 10+ additional ProTips, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Newtek Business Services Corp reported its Q1 2025 earnings, showcasing a mixed financial performance. The company achieved a notable revenue beat, with figures reaching $66.33 million compared to the forecasted $63.15 million. However, earnings per share (EPS) slightly missed expectations, coming in at $0.35 against a forecast of $0.36. Despite the EPS miss, the strong revenue growth was attributed to the company’s advancements in digital banking and alternative lending programs. Additionally, Newtek maintained its full-year EPS guidance of $2.10-$2.50, projecting a 17% growth. In terms of analyst activity, Piper Sandler and KBW analysts engaged with Newtek management to discuss sustainability in earnings and management changes. The company also highlighted its strategic focus on technology and client acquisition, which continues to drive its growth initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.